AnaptysBio, Inc.
ANAB
$20.25
-$0.115-0.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -132.59M | -140.62M | -145.23M | -165.66M | -170.12M |
| Total Depreciation and Amortization | 2.40M | 2.40M | 2.40M | 2.40M | 2.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 97.13M | 85.91M | 73.82M | 60.45M | 48.66M |
| Change in Net Operating Assets | -94.65M | -56.46M | -66.33M | -207.00K | -10.34M |
| Cash from Operations | -127.71M | -108.78M | -135.34M | -103.01M | -129.40M |
| Capital Expenditure | -372.00K | -366.00K | -358.00K | -375.00K | -502.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 80.85M | 42.00M | 95.76M | 174.35M | 146.49M |
| Cash from Investing | 80.47M | 41.63M | 95.40M | 173.97M | 145.99M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 100.77M | 100.32M | 100.84M | 100.55M | 2.21M |
| Repurchase of Common Stock | -55.98M | -4.88M | -456.00K | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -25.08M | 16.66M | 26.67M | -6.22M | 17.81M |
| Cash from Financing | 19.71M | 112.10M | 127.05M | 94.33M | 20.03M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.52M | 44.94M | 87.12M | 165.29M | 36.62M |